Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 367

1.

The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.

van den Bergh RC, Roobol MJ, Wolters T, van Leeuwen PJ, Schröder FH.

BJU Int. 2008 Nov;102(9):1068-73. doi: 10.1111/j.1464-410X.2008.07940.x. Epub 2008 Aug 18.

2.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
3.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.

PMID:
16622122
4.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
5.
6.
7.

Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE.

BJU Int. 2011 Oct;108(8 Pt 2):E237-44. doi: 10.1111/j.1464-410X.2011.10207.x. Epub 2011 Apr 20.

8.

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.

Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.

10.

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

Kawamura K, Suzuki H, Kamiya N, Imamoto T, Yano M, Miura J, Shimbo M, Suzuki N, Nakatsu H, Ichikawa T.

Int J Urol. 2008 Jul;15(7):598-603. doi: 10.1111/j.1442-2042.2008.02058.x. Epub 2008 May 2.

11.

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).

Roobol MJ, Kirkels WJ, Schröder FH.

BJU Int. 2003 Dec;92 Suppl 2:48-54.

12.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
13.

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Rannikko S, Hakama M, Tammela TL, Stenman UH.

Eur Urol. 2002 Jun;41(6):619-26; discussion 626-7.

PMID:
12074779
14.

History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.

Kawakami S, Koga F, Fujii Y, Saito K, Yamamoto S, Tatokoro M, Yonese J, Kageyama Y, Fukui I, Kihara K.

Int J Urol. 2008 Dec;15(12):1055-60. doi: 10.1111/j.1442-2042.2008.02183.x. Epub 2008 Nov 13.

15.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
16.

Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.

Nam RK, Toi A, Trachtenberg J, Klotz LH, Jewett MA, Emami M, Sugar L, Sweet J, Pond GR, Narod SA.

J Urol. 2006 Feb;175(2):489-94.

PMID:
16406978
17.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
18.

African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.

Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, Powell IJ, Eastham JA.

BJU Int. 2006 Oct;98(4):783-7.

19.
20.

The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer.

Berenguer A, Luján M, Páez A, Santonja C, Pascual T.

BJU Int. 2003 Dec;92 Suppl 2:33-8.

Supplemental Content

Support Center